WORKLATEST NEWSTEAMPARTNERSUPCOMING EVENTSCONTACT
WORKTEAMPARTNERSUPCOMING EVENTSCONTACT

THIS WAY FORWARD

Pathway Research is taking cannabis forward, developing new, personalized therapies that help people improve their health and quality of life

LATEST NEWS

May 5, 2020

Pathway Rx Advances Research that Shows Potential for Medical Cannabis to Treat COVID-19

Data collected from previous studies conducted in collaboration with Swysh and commercial partner Sundial Growers reveals that some medical cannabis cultivars can help reduce the severity and complications of COVID-19 disease

LETHBRIDGE, May 5, 2020 /CNW/ -- Pathway RX Inc. (“Pathway Rx”), a research company dedicated to developing custom cannabis therapies to treat specific diseases and Swysh Inc. (“Swysh”), a cannabinoid oral health product developer, today announced that they intend to further advance their research to evaluate the potential for medical cannabis to treat COVID-19 and its possible complications. These efforts will include the publication of more research papers and the initiation of clinical trials to validate the safety and efficacy of medical cannabis to treat COVID-19.

Full Press Release (PDF)

Pre-print Research Paper

OUR WORK

Our Research

We apply a comprehensive agnostic approach, using a combination of advanced methods to identify and isolate the medicinal properties that occur naturally in cannabis.

Targeted Conditions

Our work targets the effectiveness of cannabis compounds on specific ailments and diseases, including cancer, pain and inflammation, dementia and brain injury, anxiety, demyelination and more.

Artificial Intelligence

Our proprietary algorithms explore the intricate interplay of intracellular signalling pathways that occur in response to different conditions. We use AI to optimize and target specific cannabis compounds for personalized treatments.

Access to Genetics

With our extensive history working with cannabis and through our strategic partnerships, we have access to over 1,500 lines of cannabis genetics. Our advanced screening protocols can quickly identify relevant compounds for analysis and testing.

SEE OUR PATENTS

USP No. 62/781,631

Novel Cannabis Sativa Lines and Extracts with Anti-Cancer Properties

USP No. 62/781,647

Novel Cannabis Lines and Extracts for Treating Skin Disorders

USP No. 62/781,633

Novel Cannabis Lines and Extracts for Skin Rejuvenation and Skin Protection Against Harmful Environmental Insults

USP No. 62/781,656

Novel Cannabis Lines and Extracts With Profound Anti-Inflammatory Potencies Target TNF Pathway and Inflammation

USP No. 62/820,897

System, Method and Software for Calculation of Cannabis Drug Efficiency Index (CDEI)

OUR TEAM

Our team is made up of globally recognized experts in genetics and molecular biology, specializing in the research and development of new medical applications for cannabis compounds.

Igor Kovalchuk, PhD/MDIgor Kovalchuk, PhD/MD

Igor Kovalchuk, PhD/MD

Founder and Chief Executive Officer

Dr. Igor Kovalchuk is an award-winning expert in genetics and molecular biology with over two decades of experience in biotechnology. He's bred over 300 hybrid strains and is developing a BSc. program that specializes in industrial and medical cannabis at the University of Lethbridge.

Olga Kovalchuk, PhD/MDOlga Kovalchuk, PhD/MD

Olga Kovalchuk, PhD/MD

Founder and Chief Science Officer

Dr. Olga Kovalchuk is a professor of biological sciences; a Board of Governors' Research Chair with the University of Lethbridge; and a CIHR Research Chair in Gender, Sex and Health. She is an expert in cellular structures working to develop customized cancer treatments based on an individual's genetics.

Darryl Hudson, PhDDarryl Hudson, PhD

Darryl Hudson, PhD

Founder, Head of Cannabis Breeding

Dr. Darryl Hudson spent years studying and researching molecular biology and genetics, originally developing fertilizers for agricultural systems. Now he's a global consultant on cannabis-related projects, designing SOPs and QA standards for cultivation, extraction and analytical testing.

DongPing Li, PhD/MDDongPing Li, PhD/MD

DongPing Li, PhD/MD

Head of Pre-Clinical Development, In Vitro

Dr. Li is an expert in biomolecular sciences, with focus on molecular biology of cancer. She is leading Pathway’s in vitro molecular biology team.

Boseon Byeon, PhDBoseon Byeon, PhD

Boseon Byeon, PhD

Mathematics and Machine Learning Expert

Dr. Byeon is a trained mathematician and bioinformatician with many years of experience in managing large data sets and applying machine learning to analyzing complex patterns in large molecular data sets.

Yaroslav Ilnytskyy, PhDYaroslav Ilnytskyy, PhD

Yaroslav Ilnytskyy, PhD

Head of Bioinformatics support

Dr. Ilnytskyy has MSc degree in plant biotechnology and PhD in molecular biology of cancer. For the last 10 years, Dr. Ilnytskyy has been involved in bioinformatic analysis of genomic and transcriptomic data sets in various diseases.

VIEW MORE

OUR PARTNERS

We've built strategic partnerships with the brightest minds in the industry—organizations that share our passion and vision for cannabis science.

UPCOMING EVENTS

You'll find Pathway Research and our people participating at these upcoming events and conferences.

  • 1
  • 2
  • 3
  • 4

CONTACT US

ADDRESS

Pathway Research
4401 University Drive
Lethbridge, Alberta
T1K 3M4